Navigation Links
BUSPH study observes link between decongestant use in pregnant women and lower risk of preterm birth
Date:8/30/2010

A new study led by Boston University School of Public Health (BUSPH) epidemiologists has found that women who took over-the-counter decongestants during their pregnancies are less likely to give birth prematurely.

Preterm birth -- deliveries at less than 37 weeks' gestation -- is the leading cause of infant morbidity and mortality in developed countries, but its causes remain largely unknown, said Rohini Hernandez, the study's lead author and a doctoral candidate in epidemiology at BUSPH. In the United States, the rate of preterm delivery has increased from 9.5 percent in 1981 to 12.3 percent in 2008.

"Maybe this can provide some clues as to how to prevent preterm delivery," Hernandez said. "The more we can learn about what could potentially cause preterm birth would help our understanding in how to stop it."

The study, published online ahead of print in the journal Birth Defects Research Part A: Clinical and Molecular Teratology, found that women who took decongestants in their second or third trimesters had a roughly 58 percent reduced risk of preterm delivery compared to women who didn't use decongestants during their pregnancy. (The finding was observed only for women without preeclampsia.) The authors cautioned, however, that the findings do not necessarily imply a cause and effect relationship.

Decongestants are one of the most frequently used over-the-counter medications by pregnant women. Many, however, choose to not take any medications during their pregnancy to prevent potential harm to the developing fetus, Hernandez said.

"Medication use is a major concern for pregnant women and generally, when medications are found to have effects on the fetus, they're usually found to have adverse effects," Hernandez said. "This was surprising in that a potentially beneficial effect was found.

The researchers analyzed data from 3,271 live-born births by Massachusetts women, obtained between January 1998 and September 2008 as part of the longstanding Birth Defects Study, conducted by Boston University's Slone Epidemiology Center.

Approximately 6 percent of the study population delivered preterm, the authors wrote. Of that, 4.2 percent took decongestants while 6.7 percent did not. The women who took decongestants tended to be older, white, married, highly educated and have higher incomes.

The authors' findings supporting those from a 2006 Swedish study that found a link between prescription decongestant use and preterm delivery.

Yet Hernandez said more research is needed to see if there is an actual cause and effect relationship between decongestant use and preterm birth and if so, what element in the decongestant is producing this outcome.


'/>"/>

Contact: Elana Zak
ezak@bu.edu
617-414-1401
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. BUSPH study links rheumatoid arthritis to vitamin D deficiency
2. Study points to key genetic driver of severe allergic asthma
3. Neuronal diversity makes a difference, says Carnegie Mellon study
4. Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets
5. Texas A&M research produces tools to study stallions subfertility
6. UCI-Scripps study links cellular motors to memory
7. Coral off Puerto Ricos coast ideal case study for Gulf oil spills impact
8. Microneedle, quantum dot study opens door to new clinical cancer tools
9. New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago
10. USDA-backed study finds federal school lunches linked to childhood obesity
11. New study sheds light on painkilling system in brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), ... fourth quarter and full year ended December 31, ... for Vanda as we continued to demonstrate strong ... exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., ... pipeline with important 2017 milestones underscores Vanda,s commitment ...
(Date:2/15/2017)... Feb. 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, will ... presentation) at 8:00 AM EST on Thursday, February 16, ... clinical program, the recently announced closing of a $10.5 ... To participate in the live call and ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health ... Diameter Health technology in the hands of Lantana analysts. The high-performance platform of ... and public health entities – all those mining value from clinical data – ...
Breaking Biology Technology: